Advancing Bispecific Antibodies to the Clinic for Oncology

Cancer is one of the most intractable diseases and challenging areas of drug discovery, but bispecific antibody approaches are gaining widespread adoption by offering a multi-pronged and versatile approach for addressing cancer targets. This meeting will review preclinical and clinical results as well as investigate the remaining challenges for moving bispecific antibodies to the clinic.